(2-methylphenyl)boric acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-methylphenyl)boric acid
• 英文别名: 2-methylphenyl boric acid；2-methylphenylboric acid；o-tolylboric acid；Tolylboric acid；(2-methylphenoxy)boronic acid
• 化学式: C₇H₉BO₃
• 分子量: 151.958
• InChiKey: HTGQCLJTWPSFNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.34
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4,6-三溴-1,3,5-三甲基苯 、 (2-methylphenyl)boric acid 以11%的产率得到
  参考文献：
  名称：

  KATZ, H. E., J. ORG. CHEM., 52,(1987) N 17, 3932-3934

  摘要：

  DOI：

文献信息

• Bicyclic heterocycles, the preparation thereof, and their use as
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06114532A1

  公开（公告）日：2000-09-05

  The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula ##STR1## wherein R.sub.a to R.sub.c, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. The compounds of the above formula I wherein R.sub.c denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein R.sub.c denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.

  本发明涉及公式##STR1##的5-成员杂环融合苯衍生物，其中R.sub.a至R.sub.c，A，X和Y的定义如权利要求1中所定义，其互变异构体，立体异构体，其混合物及其盐，特别是其与具有有价值性质的无机或有机酸或碱的生理上可接受的盐。上述公式I中R.sub.c表示氰基的化合物是制备公式I的其他化合物的有价值中间体，上述公式I中R.sub.c表示以下氨基甲酰基基团之一的化合物及其互变异构体和立体异构体具有有价值的药理学性质，特别是抗血栓活性。
• Benzoheterocyclic derivatives
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US06096735A1

  公开（公告）日：2000-08-01

  A benzoheterocyclic derivative of the following formula [1]: ##STR1## and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.

  以下是该句子的中文翻译：一种苯并杂环衍生物，其化学式如下：[1]：##STR1##及其药用盐，表现出优异的抗加压素活性、加压素激动活性和催产素拮抗活性，并且可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
• Fused bicyclic pyrimidine derivatives
  申请人：Seto Shigeki

  公开号：US20050159409A1

  公开（公告）日：2005-07-21

  A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; R is a hydrogen atom, a C 1 to C 6 alkyl group, a C 1 to C 6 alkylcarbonyl group, or a C 1 to C 6 alkylsulfonyl group; m is 1 or 2; and n is 2 or 3.

  下列一种新型融合的双环嘧啶衍生物或其盐，可作为一种速激肽受体拮抗剂，尤其是作为一种NK1 受体拮抗剂，其通式如下（1）所示：其中，环A和环B分别为苯环，具有1至3个取代基（任何相邻两个取代基可结合在一起形成环）；环C为含氮环；R为氢原子、C1至C6烷基、C1至C6烷基羰基基团或C1至C6烷基磺酰基团；m为1或2；n为2或3。
• Substituted indolinones, their manufacture and their use as medicaments
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US06794395B1

  公开（公告）日：2004-09-21

  The present invention relates to substituted indolinones of general formula wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumor cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式中R1至R6和X如权利要求1所定义的取代的吲哚酮，其异构体和盐，特别是具有有价值的药理学性质，特别是对各种受体酪氨酸激酶和环/ CDK复合物以及内皮细胞和各种肿瘤细胞增殖的抑制作用的生理上可接受的盐，包含这些化合物的制药组合物，它们的用途和制备它们的过程。
• Antithrombotic quinoxazolines
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06200976B1

  公开（公告）日：2001-03-13

  Quinoxazolines having antithrombotic activity. Exemplary of those disclosed are: 4-{[6-(N-carboxymethyl-quinolin-8-yl-sulphonylamino)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, 4-{[6-(1-(N-cyclopentyl-carboxymethylcarbonylamino)-cyclo-propyl)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, and 4-{[7-(N-carboxymethylaminocarbonyl-ethylamino)-4-methyl-quinolin-2-yl]-oxo}-benzamidine.

  具有抗血栓活性的喹唑啉。其中披露的例子包括：4- [6-（N-羧甲基-喹啉-8-磺酰胺）-1-甲基-2-氧代-1,2-二氢喹啉-3-基] -甲基-苯甲酰胺,4- [6-（1-（N-环戊基-羧甲基羧酰胺）-环丙基）-1-甲基-2-氧代-1,2-二氢喹啉-3-基] -甲基-苯甲酰胺和4- [7-（N-羧甲基氨甲酰基-乙基氨基）-4-甲基喹啉-2-基] -氧代-苯甲酰胺。